Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on September 9, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on September 9, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $493.81 ($39,504) on September 9, 2026; holds 333,863 after (Indirect).
- Open-market sale: disposed of 1,202 Common Stock at $495.65 ($595,775) on September 9, 2026; holds 332,661 after (Indirect).
- Open-market sale: disposed of 1,278 Common Stock at $496.73 ($634,817) on September 9, 2026; holds 331,383 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $497.56 ($79,609) on September 9, 2026; holds 331,223 after (Indirect).
- Open-market sale: disposed of 400 Common Stock at $498.85 ($199,539) on September 9, 2026; holds 330,823 after (Indirect).
- Open-market sale: disposed of 519 Common Stock at $499.73 ($259,362) on September 9, 2026; holds 330,304 after (Indirect).
- Open-market sale: disposed of 361 Common Stock at $500.84 ($180,803) on September 9, 2026; holds 329,943 after (Indirect).
- Open-market sale: disposed of 1,017 Common Stock at $502.87 ($511,414) on September 9, 2026; holds 328,926 after (Indirect).
- Open-market sale: disposed of 1,144 Common Stock at $503.60 ($576,123) on September 9, 2026; holds 327,782 after (Indirect).
- Open-market sale: disposed of 964 Common Stock at $505.03 ($486,847) on September 9, 2026; holds 326,818 after (Indirect).
- Open-market sale: disposed of 875 Common Stock at $505.78 ($442,560) on September 9, 2026; holds 325,943 after (Indirect).
- Open-market sale: disposed of 794 Common Stock at $506.84 ($402,429) on September 9, 2026; holds 325,149 after (Indirect).
- Open-market sale: disposed of 506 Common Stock at $507.68 ($256,885) on September 9, 2026; holds 324,643 after (Indirect).
- Open-market sale: disposed of 200 Common Stock at $509.00 ($101,800) on September 9, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on September 9, 2026; holds 470,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,767,467 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-09-09 | Open-market sale | Common Stock | 80 | $494 | $39.5K | 333,863 |
| 2026-09-09 | Open-market sale | Common Stock | 1,202 | $496 | $595.8K | 332,661 |
| 2026-09-09 | Open-market sale | Common Stock | 1,278 | $497 | $634.8K | 331,383 |
| 2026-09-09 | Open-market sale | Common Stock | 160 | $498 | $79.6K | 331,223 |
| 2026-09-09 | Open-market sale | Common Stock | 400 | $499 | $199.5K | 330,823 |
| 2026-09-09 | Open-market sale | Common Stock | 519 | $500 | $259.4K | 330,304 |
| 2026-09-09 | Open-market sale | Common Stock | 361 | $501 | $180.8K | 329,943 |
| 2026-09-09 | Open-market sale | Common Stock | 1,017 | $503 | $511.4K | 328,926 |
| 2026-09-09 | Open-market sale | Common Stock | 1,144 | $504 | $576.1K | 327,782 |
| 2026-09-09 | Open-market sale | Common Stock | 964 | $505 | $486.8K | 326,818 |
| 2026-09-09 | Open-market sale | Common Stock | 875 | $506 | $442.6K | 325,943 |
| 2026-09-09 | Open-market sale | Common Stock | 794 | $507 | $402.4K | 325,149 |
| 2026-09-09 | Open-market sale | Common Stock | 506 | $508 | $256.9K | 324,643 |
| 2026-09-09 | Open-market sale | Common Stock | 200 | $509 | $101.8K | 324,443 |
| 2026-09-09 | Option exercise/conversion | Stock Option | 9,500 | — | — | 470,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Option exercise/conversion (9,500 shares) |
| 2026-09-09 | Open-market sale (80 shares) |
| 2026-09-09 | Open-market sale (1,202 shares) |
| 2026-09-09 | Open-market sale (1,278 shares) |
| 2026-09-09 | Open-market sale (160 shares) |
| 2026-09-09 | Open-market sale (400 shares) |
| 2026-09-09 | Open-market sale (519 shares) |
| 2026-09-09 | Open-market sale (361 shares) |
| 2026-09-09 | Open-market sale (1,017 shares) |
| 2026-09-09 | Open-market sale (1,144 shares) |
| 2026-09-09 | Open-market sale (964 shares) |
| 2026-09-09 | Open-market sale (875 shares) |
| 2026-09-09 | Open-market sale (794 shares) |
| 2026-09-09 | Open-market sale (506 shares) |
| 2026-09-09 | Open-market sale (200 shares) |
| 2026-09-09 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.